tbuckley/cabot-search huggingface dataset:
Phase I/II trial of bortezimib and pemetrexed in patients with advanced non-small cell lung cancer
Authors: R. B. Natale, M. McKinley, J. Hilger, T. Myers
Journal: Journal of Clinical Oncology (2007)

18145 Background: Bortezomib (Vc) is a novel proteosome inhibitor with activity in several malignancies including multiple myeloma, mantle cell lymphoma, and NSCLC. In NSCLC, Vc has additive activity combined with carboplatin and gemcitabine in first line and with docetaxel in second line treatment. Pemetrexed (P) is active in NSCLC and preclinical data suggests a pro-apoptotic synergy between Vc and P. Therefore, we initiated a phase I/II dose finding study of Vc + P in previously-treated patients (pts) with advanced or metastatic NSCLC. Methods: Fifteen pts have been accrued to 3 of 4 planned dose levels of Vc + P. Starting doses (and # pts treated) were Vc 1.4 mg/m 2 day 1 &amp; 8 + P 400 mg/m 2 day 1 every 3 weeks (3 pts). The 2nd and 3rd dose levels were Vc 1.6 mg/m 2 day 1 &amp; 8 + P 500 mg/m 2 day 1 (8 pts, 5 new + 3 from dose level 1) and Vc 1.8 mg/m 2 day 1 &amp; 8 + P 500 mg/m 2 day 1 (7 pts). Results: 15 pts are evaluable for response and toxicity and include 8 males, 7 females, median age 67 (range, 55–82), PS 0/1 (3/12 pts), median of 2 prior therapies (range 1–3). Confirmed PRs occurred in 2 pts (13%) and stable disease in 5 (33%). Dose limiting toxicities consisted of grade 4 fatigue (1 pt) and neutropenia/fever (1 pt) at dose level 2, and grade 3 abdominal pain and fatigue (1 pt) and grade 3 diarrhea and vomiting (1 pt) at dose level 3. Conclusions: The above combination is safe at the doses tested thus far and active in pts with heavily pretreated, advanced NSCLC. We are currently exploring Vc 2.0 mg.m 2 Day 1 &amp; 8 + P 500 mg/m 2 day 1 every 3 weeks to determine the MTD and plan a multi-site Phase II study to determine response rate and survival in a larger pt population. No significant financial relationships to disclose.
Combined intra-arterial cisplatin, intravenous chemotherapy, and chemoradiotherapy is an effective program for treating advanced SCC of the head and neck: An analysis of 23 patients with a median follow-up of 6.1 years
Authors: T. P. O'Connor, R. R. Batra, D. A. Mobarek, D. M. Kirkel, A. Schwarsin, A. Sharma, W. O. Bank, W. R. Wilson, I. A. Tabbara, R. S. Siegel
Journal: Journal of Clinical Oncology (2007)

16535 Background: Aggressive chemotherapy combined with radiation increases organ preservation and provides locoregional control in advanced head and neck (H&amp;N) cancer. Intra-arterial (IA) cisplatin can provide higher dose intensity but does not control distant disease. We evaluated a program that consisted of intra-arterial and intravenous chemotherapy combined with chemoradiotherapy. Methods: The course of 23 patients treated with four weekly IA doses of cisplatin (150 mg/m 2 ) with IV sodium thiosulfate rescue, then two cycles IV paclitaxel (175 mg/m 2 , day 1), ifosfamide (1,000 mg/m 2 and mesna 600 mg/m 2 , days 1–3), and cisplatin (60 mg/m 2 , day 1) (TIP), and followed by radiation to 70 Gy combined with weekly paclitaxel (30 mg/m 2 ) and amifostine (740 mg/m 2 TIW) was analyzed. One patient received one cycle of cisplatin/5-FU and one cycle of TIP instead of 2 cycles of TIP. Endpoints were recurrence free survival (RFS) and overall survival (OS). Results: Of twenty-three patients, 20 were men. The median age was 57 years (range 45–70) and median follow-up was 6.1 years (range 4.1–7.9). Eighteen had long smoking histories. Seventeen completed treatment (74%). Of the 6 who did not complete the program, two had resistant tumors, one had an adverse reaction to IA therapy, and three were noncompliant. Of 23 patients, 14 are alive, 13 without evidence of disease recurrence; one patient recurred and was salvaged by surgery. Five patients recurred and died of metastatic H&amp;N cancer. One patient recurred, was salvaged with surgery and later died of lung cancer without evidence of H&amp;N cancer. The RFS is 56.5% and the OS is 60.8%. Adverse events were infrequent and included 1 patient who had facial swelling during IA therapy and 2 patients who developed osteonecrosis of the mandible, one while continuing to smoke 6 months after therapy and the other 3 years after therapy following tooth extraction. Conclusions: A program consisting four doses of intra-arterial cisplatin followed by two cycles of IV TIP and chemoradiotherapy is effective in treating locally advanced SCC of the H&amp;N and was generally well tolerated. No significant financial relationships to disclose.
Vasculitis Associated with Large Granular Lymphocytes Leukemia
Authors: Alexandra Audemard, Thierry Lamy, Benoit Bareau, Felipe Suarez, Margaret Macro, Loic Guillevin, Flore Sicre, Florence Truquet, Salaun Veronique, Jerome Rey, Estibaliz Lazzaro, Jonathan Boutemy, Laurence Verneuil, Stephane Cheze, Nicolas Schleinitz, Thierry Lobbedez, Loic Geffray, Cindy Castrale, Boris Bienvenu
Journal: Blood (2012)
Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014
Authors: Sita D. Bhella, Rumina Musani, Anna Porwit, Anne Tierens, Vikas Gupta, Aaron D. Schimmer, Andre C Schuh, Karen W.L. Yee, Mark D. Minden
Journal: Blood (2015)
Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin®; 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin’s Lymphoma (NHL).
Authors: Andrew M. Evens, David Patton, Stewart Spies, Smitha Sivaraman, M.Wayne Saville, See Phan, Richard Miller, Leo I. Gordon
Journal: Blood (2005)
Consistency in regional trends of aggressiveness in cancer care near the end of life for elderly Americans, 1991–2000
Authors: C. C. Earle, M. Landrum, S. Jeffrey, B. Neville, J. Weeks, J. Ayanian
Journal: Journal of Clinical Oncology (2006)

6004 Background: We have previously developed and reported on performance measures assessing the aggressiveness of cancer treatment near the end of life for selected cancers during 1993–96. Methods: We compared the care delivered in the 77 Health Care Service Areas (HCSAs) monitored by the Surveillance, Epidemiology, and End Results (SEER) program to all Medicare-eligible patients aged 65 and over who died of cancer (any diagnosis) between 1991 and 2000. We used hierarchical regression models to estimate regional variation in both levels and trends of each indicator. We then ranked each region according to the model-estimated rate of each indicator and computed the correlation among relative ranks of each region over the ten-year study period. Results: 215,488 patients met eligibility criteria. Within this broader and more recent sample we confirmed previous observations of steadily and significantly increasing use of chemotherapy within 2 weeks of death, emergency room visits, and intensive care unit admissions in the last month of life, and, among those admitted to hospice, an increasing proportion of late admissions within 3 days of death. There was significant regional variation in all measures, but the relative rankings of health care service areas from one year to the next were stable, with correlations of ranks ranging from .91–.98 from 1991–1992, and .66–.84 over the 5-year span from 1991–1995. Because of significant regional variation in trends, we found only moderate correlations ranging from .40–.61 over the entire decade. Conclusions: Cancer treatment near the end of life continued to become increasingly aggressive over the 1990s, however, there was significant regional variation in trends. The stability of regional practice patterns supports the reliability of these measures for quality surveillance purposes. [Table: see text] No significant financial relationships to disclose.
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
Authors: Aditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, Natella Rakhmanina, Mohammed Rassool, Rana Chakraborty, Jagmohan Batra, Pope Kosalaraksa, Wicharn Luesomboon, Danielle Porter, Yongwu Shao, Michael Myers, Lillian Ting, Devi SenGupta, Erin Quirk, Martin S Rhee
Journal: The Lancet HIV (2016)
Clinical, Biochemical, and Radiographic Responses to Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-Associated Herpes Virus (KSHV) – Associated Multicentric Castleman's Disease.
Authors: Thomas Uldrick, Mark N. Polizzotto, Deirdre O'Mahony, Karen Aleman, Kathy Wyvill, Seth Steinberg, Stefania Pittaluga, Richard F Little, Robert Yarchoan
Journal: Blood (2009)
Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia
Authors: Yang Liu, Min Ni, Aldo M. Roccaro, Xavier Leleu, Yong Zhang, Abdel Kareem A. Azab, Feda Azab, Patricia Maiso, Hai T Ngo, Antonio Sacco, Brittany Morgan, Myles Brown, Irene Ghobrial
Journal: Blood (2010)
The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP
Authors: Chan Yoon Cheah, Martin Hutchings, Kirsty Rady, Kerry J. Savage, Musa F. Alzahrani, Laurie H. Sehn, Sally Barrington, George Mikhaeel, Roopesh R. Kansara, Jakob Werner Hansen, Daniel Smith, Karen Juul Mylam, Thomas Stauffer Larsen, Staffan Holmberg, Maja Juul, Sabrina Cordua, Michael Roost Clausen, Kkristina Buchardi Jensen, Martin Bogsted, Hans Erik Johnsen, Joseph M. Connors, Peter de Nully Brown, John F. Seymour, Diego Villa, Tarec Christoffer El-Galaly
Journal: Blood (2015)
Usual Clinical Parameters Underestimate the Incidence and Significance of Erythropoietin Deficiency as a Risk Factor for Death in Sickle Cell Disease.
Authors: Santosh Saraf, Seema Sidhwani, Mohammed Farooqui, Stephen Vara, Joseph DeSimone, Robert Molokie, Yogenthiran Saunthararajah
Journal: Blood (2007)
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Authors: Fara Brasó-Maristany, Simone Filosto, Steven Catchpole, Rebecca Marlow, Jelmar Quist, Erika Francesch-Domenech, Darren A Plumb, Leila Zakka, Patrycja Gazinska, Gianmaria Liccardi, Pascal Meier, Albert Gris-Oliver, Maggie Chon U Cheang, Anna Perdrix-Rosell, Manar Shafat, Elodie Noël, Nirmesh Patel, Kristen McEachern, Maurizio Scaltriti, Pau Castel, Farzana Noor, Richard Buus, Sumi Mathew, Johnathan Watkins, Violeta Serra, Pierfrancesco Marra, Anita Grigoriadis, Andrew N Tutt
Journal: Nature Medicine (2016)
New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,
Authors: Angelo Agathanggelou, Anastasia Zlatanou, Ahmed Gulshanara, Grant Stewart, Pamela R Kearns, Guy Pratt, Paul AH Moss, A. Malcolm R Taylor, Frederic Colland, Tatjana Stankovic
Journal: Blood (2011)
Antiviral treatment and liver‐related complications in hepatitis delta
Authors: Anika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, Janina Kirschner, Birgit Bremer, Patrick Lehmann, Svenja Hardtke, Katja Deterding, Kerstin Port, Max Westphal, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer
Journal: Hepatology (2016)

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis. Pegylated interferon alfa (PEG‐IFNα) is effective in only 25%‐30% of patients and is associated with frequent side effects. The aim of this study was to analyze the clinical long‐term outcome of hepatitis delta in relation to different antiviral treatment strategies. We studied 136 anti‐HDV‐positive patients who were followed for at least 6 months in a retrospective single‐center cohort (mean time of follow‐up, 5.2 years; range, 0.6‐18.8). Liver cirrhosis was already present in 62 patients at first presentation. Twenty‐nine percent of patients did not receive any antiviral treatment, 38% were treated with interferon alfa (IFNα)‐based therapies, and 33% received nucleos(t)ide analogues (NAs) only. Clinical endpoints defined as hepatic decompensation (ascites, encephalopathy, and variceal bleeding), hepatocellular carcinoma, liver transplantation, and liver‐related death developed in 55 patients (40%). Patients who received IFNα‐based therapies developed clinical endpoints less frequently than those treated with NA ( P = 0.02; HR, 4.0) or untreated patients ( P = 0.05; HR, 2.2; 17%, 64%, and 44%), respectively, which was significant in both chi‐square and Kaplan‐Meier analysis. In addition, considering various clinical and virological parameters, IFNα therapy was independently associated with a more benign clinical long‐term outcome in multivariate logistic regression analysis ( P = 0.04; odds ratio, 0.25; 95% confidence interval, 0.07‐0.9). Loss of HDV RNA during follow‐up was more frequent in IFNα‐treated patients and strongly linked with a lower likelihood to experience liver‐related complications. Conclusion : IFNα‐based antiviral therapy of hepatitis delta was independently associated with a lower likelihood for clinical disease progression. Durable undetectability of HDV RNA is a valid surrogate endpoint in the treatment of hepatitis delta. (H epatology 2017;65:414‐425).
Integrin-Linked Kinase Regulates Vasomotor Function by Preventing Endothelial Nitric Oxide Synthase Uncoupling
Authors: Beatriz Herranz, Susana Marquez, Brenda Guijarro, Enrique Aracil, Clara Aicart-Ramos, Ignacio Rodriguez-Crespo, Isabel Serrano, Manuel Rodríguez-Puyol, Carlos Zaragoza, Marta Saura
Journal: Circulation Research (2011)

Atherosclerotic lesions develop in regions of disturbed flow, whereas laminar flow protects from atherogenesis; however, the mechanisms involved are not completely elucidated. Integrins are mechanosensors of shear stress in endothelial cells, and integrin-linked kinase (ILK) is important for blood vessel integrity and cardiovascular development.To explore the role of ILK in vascular function by studying conditionally ILK-deficient (cKO) mice and human atherosclerotic arteries.ILK expression was detected in the endothelial cell layer of nonatherosclerotic vessels but was absent from the endothelium of atherosclerotic arteries. Live ultrasound imaging revealed that acetylcholine-mediated vasodilatation was impaired in cKO mice. These mice exhibited lowered agonist-induced nitric oxide synthase (NOS) activity and decreased cyclic guanosine monophosphate and nitrite production. ILK deletion caused endothelial NOS (eNOS) uncoupling, reflected in reduced tetrahydrobiopterin (BH4) levels, increased BH2 levels, decreased dihydrofolate reductase expression, and increased eNOS-dependent generation of superoxide accompanied by extensive vascular protein nitration. ILK reexpression prevented eNOS uncoupling in cKO cells, whereas superoxide formation was unaffected by ILK depletion in eNOS-KO cells, indicating eNOS as a primary source of superoxide anion. eNOS and ILK coimmunoprecipitated in aortic lysates from control animals, and eNOS-ILK-shock protein 90 interaction was detected in human normal mammary arteries but was absent from human atherosclerotic carotid arteries. eNOS-ILK interaction in endothelial cells was prevented by geldanamycin, suggesting heat shock protein 90 as a binding partner.Our results identify ILK as a regulatory partner of eNOS in vivo that prevents eNOS uncoupling, and suggest ILK as a therapeutic target for prevention of endothelial dysfunction related to shear stress-induced vascular diseases.
Renal Adverse Effect of Anagrelide in Patients with Myeloproliferative Neoplasms
Authors: Yeo-Kyeoung Kim, Soo-Young Bae, Li Yu, Nan-Young Kim, Se Ryeon Lee, Jae-Sook Ahn, Deok-Hwan Yang, Il-Kwon Lee, Je-Jung Lee, Hyeoung-Joon Kim
Journal: Blood (2011)
High Dose Cyclophosphamide (HD CY) without Hematopoietic Stem Cell Transplantation (HSCT) in Refractory Severe Autoimmune Diseases: 11 Year Experience in Over 100 Patients.
Authors: Amy E. DeZern, Michelle Petri, Douglas Kerr, Daniel Drachman, Adam Kaplin, Charles Hesdorffer, Grant Anhalt, Fredrick Wigley, Richard J. Jones, Robert Brodsky
Journal: Blood (2009)
Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients
Authors: Animesh Pardanani, Ramy A Abdelrahman, Kebede Begna, Darci Zblewski, Aref Al-Kali, Mrinal M. Patnaik, William Hogan, Terra L Lasho, Christy Finke, Curtis A. Hanson, Mark R. Litzow, Ayalew Tefferi
Journal: Blood (2013)
Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome Among HIV-Infected Individuals In The Center For AIDS Research Network Of Integrated Clinical Systems
Authors: Satish Gopal, Monita Patel, Elizabeth Yanik, Greer Burkholder, Erin Reid, Benigno Rodriguez, Steven Deeks, Kenneth Mayer, Richard Moore, Mari Kitahata, Joseph Eron, Kristy L. Richards
Journal: Blood (2013)
The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival
Authors: Hiroto Ohguchi, Teru Hideshima, Manoj Bhasin, Gullu Gorgun, Loredana Santo, Michele Cea, Naoya Mimura, Rikio Suzuki, Yu-Tzu Tai, Ruben D. Carrasco, Noopur S. Raje, Paul G. Richardson, Hideo Harigae, Takaomi Sanda, Kenneth C. Anderson
Journal: Blood (2015)
Organ Donor Registration Policies and the Wrongness of Forcing People to Think of Their Own Death
Authors: Tomasz Żuradzki, Katarzyna Marchewka
Journal: The American Journal of Bioethics (2016)

MacKay and Robinson (2016) claim that some legal procedures that regulate organ donations (VAC, opt-in, opt-out) bypass people's rational capacities and thus are “potentially morally worse than MAC...
Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial
Authors: Jeffrey W Taub, Jason N Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David R. Head, Susana C. Raimondi, Betsy A. Hirsch, Robert B. Gerbing, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis
Journal: Blood (2014)
Update of a phase II trial of bevacizumab in combination with hormonal therapy to reverse acquired estrogen independence in metastatic breast cancer patients
Authors: C. Falkson, J. Rossman, L. Nabell, J. Carpenter, A. Forero, Y. Kim, M. Saleh
Journal: Journal of Clinical Oncology (2009)

e12027 Background: Metastatic breast cancer (MBC) remains the second most common cause of cancer death in women in the US. More than 80% of breast cancers are potentially hormone responsive, but resistance eventually precludes cure. Various mechanisms of acquired hormone resistance have been postulated. Our Breast Cancer SPORE showed that increased expression of VEGF caused acquired tamoxifen resistance in MCF-7 xenografts. VEGF over-expressing MCF-7 cells displayed increased tumor growth rates and estrogen independence in vivo, and reversal of VEGF over-expression in vivo returned tumors to estrogen dependent growth. Methods: We hypothesized that adding the anti-VEGF monoclonal antibody, bevacizumab, to hormonal therapy would result in reversal of acquired hormone resistance. This multi-center, open-label, single arm phase II study was designed to evaluate safety and efficacy of this combination. Primary end point was time to progression (TTP), and the secondary endpoints were response rate and toxicity. Eligible patients had MBC and had progressed on hormonal therapy after previously responding for at least 6 months.Results: We previously reported a planned interim analysis. Results of further analysis after completion of accrual will be reported here. All 27 patients were female with median age of 63 years, and all had ER and/or PR positive MBC. Patients were continued on the same hormonal therapy to which they had become refractory, and bevacizumab (15mg/kg IV every 3 weeks) was added. Treatment was stopped early in 3 patients due to a grade 3 leg ulcer, grade 3 hypertension, and grade 3 fatigue, respectively. Overall, the therapy was tolerated well, and no treatment related deaths or thromboembolic events were seen. Stable disease was documented in 18 (66%) patients. There were no complete or partial responses. Updated median TTP will be reported. Conclusions: The combination of bevacizumab plus hormonal therapy is well tolerated in patients with metastatic breast cancer. This combination may prolong the TTP with acceptable toxicity. Further investigation utilizing this combination in metastatic breast cancer are ongoing. [Table: see text]
Branch-Specific Microtubule Destabilization Mediates Axon Branch Loss during Neuromuscular Synapse Elimination
Authors: Monika S. Brill, Tatjana Kleele, Laura Ruschkies, Mengzhe Wang, Natalia A. Marahori, Miriam S. Reuter, Torben J. Hausrat, Emily Weigand, Matthew Fisher, Andrea Ahles, Stefan Engelhardt, Derron L. Bishop, Matthias Kneussel, Thomas Misgeld
Journal: Neuron (2016)

Developmental axon remodeling is characterized by the selective removal of branches from axon arbors. The mechanisms that underlie such branch loss are largely unknown. Additionally, how neuronal resources are specifically assigned to the branches of remodeling arbors is not understood. Here we show that axon branch loss at the developing mouse neuromuscular junction is mediated by branch-specific microtubule severing, which results in local disassembly of the microtubule cytoskeleton and loss of axonal transport in branches that will subsequently dismantle. Accordingly, pharmacological microtubule stabilization delays neuromuscular synapse elimination. This branch-specific disassembly of the cytoskeleton appears to be mediated by the microtubule-severing enzyme spastin, which is dysfunctional in some forms of upper motor neuron disease. Our results demonstrate a physiological role for a neurodegeneration-associated modulator of the cytoskeleton, reveal unexpected cell biology of branch-specific axon plasticity and underscore the mechanistic similarities of axon loss in development and disease.
Health bodies urge UK government to begin phasing out coal power
Authors: Gareth Iacobucci
Journal: BMJ (2016)

An alliance of UK health organisations has urged the government to fulfil its pledge to phase out coal power as soon as possible to protect the public’s health.

In its new report,1 published on Tuesday 18 October, the UK Health Alliance on Climate Change, which includes medical royal colleges and The BMJ among its members, urges the government to legislate to end the burning of coal by 2025 to fulfil a pledge made by ministers almost a year ago.2

The report, A Breath of Fresh Air , said that …
GW26-e2296 Structure, Detect and Evaluate a Tissue-Engineered 3D Cardiac Model Based on Decellularized Heart Scaffold In Vitro
Authors: Yingjin Lu, Liang Hou, Wei Liu, Xiuzhen Zhang, Hong Xu, Yanchun Ding, Xiuli Wang, Guofeng Wei
Journal: Journal of the American College of Cardiology (2015)
Androgen deprivation therapy may be linked to increased risk of dementia
Authors: Jacqui Wise
Journal: BMJ (2016)

Androgen deprivation therapy (ADT), a common treatment for prostate cancer, may be associated with an increased risk of dementia, new research in JAMA Oncology has found.1

Androgen deprivation therapy is used to reduce levels of androgens as they stimulate prostate cancer cells to grow. The approach has shown survival benefit in some patients but has also been associated with adverse health effects—for example, growing evidence supports a link between ADT and neurocognitive dysfunction.

The researchers …
Allogeneic Stem-Cell Transplantation for AML and MDS with Tresosulfan Compared with Busulfan-Based Regimens; Reduced Toxicity Vs. Reduced Intensity
Authors: Avichai Shimoni, Noga Shem-Tov, Ivetta Danylesko, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler
Journal: Blood (2011)